Last updated on December 2019

Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: NIDDM
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:- Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study. - Male or female, age 18 years or older at the time of signing informed consent. - Type 2 diabetes mellitus diagnosis.- Treatment with either 1 or 2 oral antidiabetic medications.

  • Current member of a commercial or Medicare health plan with pharmacy benefits.- Recorded HbAlc value within last 90 days prior to randomization. - Further intensification with an additional antidiabetic oral or injectable medication is indicated to achieve glycemic target at the discretion of the study physician according to approved labelling.

Exclusion Criteria: - Previous randomization in this study - Treatment with any medication for the indication of diabetes other than metformin in a period of 30 days before the day of eligibility assessment. Temporary/emergency use of any type of insulin is allowed, as is prior insulin treatment for gestational diabetes - Contraindications to semaglutide according to the Food and Drug Administration approved label - Female who is pregnant, breastfeeding or intends to become pregnant - Participation in another clinical trial

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.